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David G. Maloney1T cell diversity posttransplantation is thought to be severely restricted, based on T cell receptor b-chain im-
munophenotyping or spectratyping. Using b-chain sequencing, we studied CD4 T cell diversity in 2 adult pa-
tients undergoing ‘‘lymphoablative’’ conditioning with cyclophosphamide (Cy), total body irradiation (TBI),
and antithymocyte globulin (ATG) and autologous transplantation of hematopoietic cells depleted of T cells
by enrichment for CD34 cells. The indication for the transplantation was systemic sclerosis (SSc) or multiple
sclerosis (MS). Pretransplantation, the estimated number of distinct b chains (the minimum number of CD4 T
cell clones) in the 2 patients was 600,000 to 700,000, similar to the number in a healthy control. This number
was 200,000 to 500,000 at 1 month posttransplantation and 400,000 to 1,600,000 at 12 months posttransplan-
tation. In conclusion, the number of T cells early after lymphoablative conditioning and autologous CD34 cell
transplantation may be more diverse than previously appreciated, possibly because many T cell clones survive
the conditioning or are reinfused with the graft. Thus, the therapy may not be completely T cell lymphoablative.
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sclerosisThe diversity of T cells posttransplantation has
been studied primarily by the flow cytometric detec-
tion of T cell receptor b-chain families (with variable
region-specific monoclonal antibodies [mAbs]) or by
spectratyping, that is, electrophoretic detection of var-
ious lengths of the b-chain complementarity-deter-
mining region 3 (CDR3) segments of rearranged
b-chain genes [1-21].With both techniques, the reper-
toire of posttransplantation T cells appears to be
skewed; that is, some T cell clones appear to be over-
represented, whereas others appear to be absent.
This phenomenon is particularly prominent in the first
several months posttransplantation and in patients
who received T cell–depleted grafts (eg, in vivo with
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6/j.bbmt.2008.09.013cell graft enrichment). Normalization of the flow cy-
tometry or spectratyping findings in adults typically
takes at least 2 years [14,22-25]. This suggests that in
the first several months posttransplantation, the diver-
sity of T cells is severely restricted, and that it takes at
least 2 years to restore the diversity to normal. But the
skewed Vb representation by flow cytometry or spec-
tratyping also may reflect expansion of certain T cell
clones, rather than restricted T cell diversity [26].
The expanded clones may make the detection of non-
expanded clones difficult or impossible, especially if
specimens contain only a small number of T cells. In
the present study, we used a sequencing-based method
and specimens containing large numbers of T cells
(obtained by apheresis) to estimate the number of
distinct b chains (as a surrogate of T cell diversity).SUBJECTS AND METHODS
Three individuals were studied: a 46-year-old fe-
male with systemic sclerosis (SSc) undergoing autolo-
gous CD34 cell transplantation using conditioning
with cyclophosphamide (Cy; 120 mg/kg), total body
irradiation (TBI; 8 Gy), and ATG (90 mg/kg) [27];
a 28-year-old male with multiple sclerosis (MS)1373
Table 1. Determination of CD4 T Cell Diversity in a Healthy Control and 2 Patients
Subject (time point) [CD4 T
cells per mL blood*]
Number of
Vb17+ CD4+ T
cells analyzed Rearrangement
Frequency of
Vb17 gene, %
Frequency of
Jb (1.4, 1.5, or
2.6) gene, %
Peak
size, %
Number of distinct
sequences within
the peak(s)
Diversity
( 106)
Healthy control 105 Vb17-Jb1.5 1.6 13 18.5 140 0.4
106 Vb17-Jb1.4 1.6 2.9 20.2 60 0.6
105 Vb17-Jb1.4 1.6 2.9 20.2 60 0.6
SSc patient (pretransplantation) 106 Vb17-Jb1.4 1.0 0.6 35.1 12 0.7
105 Vb17-Jb1.4 1.0 0.6 35.1 11 0.6
SSc patient (1 month posttransplantation)
[CD4 5 26]
105 Vb17-Jb1.4 0.7 6.7 100.0 12 0.3
105 Vb17-Jb2.6 0.7 2.0 100.0 25 0.2
SSc patient (12 months posttransplantation)
[CD4 5 347]
105 Vb17-Jb1.4 1.5 2.1 100.0 16 0.5
105 Vb17-Jb2.6 1.5 1.1 100.0 70 0.4
MS patient (1 month posttransplantation)
[CD4 5 5]
105 Vb17-Jb1.4 0.5 3.3 100.0 74 0.4
105 Vb17-Jb2.6 0.5 1.7 100.0 45 0.5
MS patient (12 month posttransplantation)
[CD4 5 186]
105 Vb17-Jb1.4 0.5 2.8 100.0 230 1.6
105 Vb17-Jb2.6 0.5 1.8 100.0 >112† >1.2
*5th to 95th percentile reference range, 416 to 1437/mL.
†Plateau of the curve showing the number of distinct clones versus the number of clones sequenced had not been reached by the time 180 clones were
sequenced.
1374 Biol Blood Marrow Transplant 14:1373-1379, 2008J. Storek et al.undergoing autologous CD34 cell transplantation us-
ing the same conditioning [28]; and a healthy 44-year-
old male (control). The 2 patients were selected from
a cohort of 56 patients undergoing transplantation
for SSc or MS based on their willingness to undergo
research apheresis at 1 and 12 months posttransplanta-
tion. Because the transplantation was performed for
autoimmune diseases, it was designed to be maximally
lymphoablative. Thus, not only were Cy, TBI, and
ATG used, but also the autologous graft was enriched
immunomagnetically for CD34 cells. The typical
composition of the graft using this protocol was 261
 106 CD34 cells, 2  106 CD4 T cells, and 1  106
CD8 T cells [29].
Immune reconstitution of the whole cohort has
been described in detail previously [29]. The immuno-
logic studies of the 2 patients were representative of
the whole cohort, in that their CD4 T cell counts
were very low at 1 month posttransplantation and
moderately low at 12 months posttransplantation
(Table 1, first column), and their CD4 and CD8
Vb-Jb spectratypes exhibited a lower-than-normalme-
dian number of peaks at both 1 month and 12 months
posttransplantation (data not shown). For the studies
of posttransplantation T cell diversity, 8-L mononu-
clear cell apheresis (COBE Spectra; CaridianBCT,
Lakewood, CO) was performed at 1 month and 12
months posttransplantation. For the SSc patient, pre-
transplantation T cell diversity also was studied, using
cells obtained as the flow-through (CD34-negative)
fraction during the immunomagnetic selection of
CD34 cells from the autologous graft (apheresis prod-
uct). The flow-through fraction of the graft was un-
available for the MS patient.
Clinically, the underlying disease was at least par-
tially stabilized. The SSc patient’s Rodnan skin score
was 48 pretransplantation, 39 at 1 year posttransplan-
tation, 32 at 2 years posttransplantation, and 42 at 4
years posttransplantation, and lung function (limitedpretransplantation) was stable for 4 years posttrans-
plantation. TheMS patient’s extended disability status
scale was 2.0 at 1 year pretransplantation; 7.0 to 7.5
immediately pretransplantation; 8.0 at 1 year, 2 years,
and 3 years posttransplantation; and 7.5 at 4 years post-
transplantation. No new T2 magnetic resonance
imaging (MRI) lesions were detected on any available
determination (3, 6, and 12 months posttransplanta-
tion). The study design received Institutional Review
Board approval.
The number of distinct b chains was estimated us-
ing the method of Arstila et al. [30], with minor
modifications. The focus was on CD4 T cells, because
these cells appear to play an important role in the path-
ogenesis of SSc and MS, and their quantitative defi-
ciency appears to play an important role in transplant
recipients’ susceptibility to infection [31-34]. The
frequency of cells using Vb17 among CD4 T cells
was determined by flow cytometry, using Vb17
antibody-fluorescein conjugate (Beckman-Coulter/
Immunotech, Fullerton, CA) and CD4 antibody-phy-
coerythrin conjugate (BD Biosciences, San Jose, CA)
(Table 1, fourth column). To maximize the sensitivity
and specificity of the downstream polymerase chain re-
action (PCR), Vb171CD41cells were sorted to. 95%
purity using FACS Vantage (BD Biosciences). After
centrifugation, the cells were resuspended into 100
mL of solution D, prepared by mixing 7 mL of b-mer-
captoethanol (14.2 M) with 100 mL of lysis buffer
from the Absolutely RNA Microprep kit (Stratagene,
La Jolla, CA). RNA was extracted using the same kit,
and cDNA was synthesized using the Superscript II
RNase H- Reverse-Transcriptase Kit (Invitrogen)
and Oligo(dT)12-18 primers (Invitrogen). Each reverse
transcription yielded 60 mL of cDNA. The cDNA was
used for real-time PCR to determine the frequency of
cells using Jb1.4 (or Jb1.5 or Jb2.6) (Table 1, fifth
column), for spectratyping to determine the size of
the CDR3 peak(s) of interest (Table 1, sixth column),
Biol Blood Marrow Transplant 14:1373-1379, 2008 1375Posttransplantation T Cell Diversityand for gel electrophoresis for cloning and sequencing
to determine the number of different sequences within
the peak(s) (Table 1, seventh column). Details of the
determinations of the frequency of cells using Jb1.4
(or Jb1.5 or Jb2.6), the size of the CDR3 peak(s) of in-
terest, and the number of different sequenceswithin the
peak(s), are provided below. Diversity (total number of
distinct Vb chains among CD4 T cells, ie, the mini-
mum number of CD4 T cell clones; Table 1, last
column) was calculated as
Number of distinct sequences within the peakðsÞ
Peak size

%

100  frequency of Jb gene %
100  frequency of Vb17 gene %100:
Because the determination of diversity gave a simi-
lar result when 105 or 106 sorted Vb171CD41 cells
were used, 105 cells were used for most determinations
(Table 1, second column). Note that in accordance
with the ImMunoGeneTics nomenclature [35], Vb17
is TRBV19, Jb1.4 is TRBJ1-4, Jb1.5 is TRBJ1-5,
and Jb2.6 is TRBJ2-6.
The frequencyof cells using Jb1.4 (or Jb1.5 or Jb2.6)
was determined by real-time PCR. The forward primer
was AAGGGTACAGCGTCTCTCGG (Vb17); the
reverseprimerwasAGACAGAGAGCTGGGTTCCA
(Jb1.4), CAGCATTTTGGTGATGGGAC (Jb1.5),
ACTTTCGGGGCCGGCAGCAG ((Jb1.6), or GAG
GTCGCTGTGTTTGAGCC (C); and the probe
was FAM- TCCTTTCCTCTCACTGTGACATC
GGC-TAMRA (MegaBases, Chicago, IL). Each PCR
reaction contained 5 mL of cDNA as a template, 1 U
of Platinum-Taq polymerase (Invitrogen), 2.5 mM
MgCl2, 500 mM dNTPs, 500 nM each primer, 250
nM probe, and 200 nM Blue-636 reference (Mega-
Bases). The reactions were run at 95C for 5 minutes,
then at 94C for 30 seconds, 58C for 30 seconds, and
72C for 30 seconds for 40 cycles, using an ABI Prism
7700 Sequence Detector (PE Biosystems, Norwalk,
CT). Endpoint-normalized fluorescence (Rn) was
detected. Vb17-VC was considered the standard.
The Jb1.4 percentage was calculated as RnVb17-Jb1.4/
RnVb17-VC  100 (analogous for Jb1.5 and Jb2.6) using
the ABI 7700 software (PE Biosystems). Vb17-Jb1.4
(Vb17-Jb1.5, Vb17-Jb2.6) and Vb17-VC were assumed
tohave the sameamplification rate.This assumptionwas
verified by multiple 10-fold dilutions of the templates.
The sizes of the CDR3 spectratyping peaks of in-
terest were determined as follows: Vb17-Jb1.4,
Vb17-Jb1.5, or Vb17-Jb2.6 segments were separately
amplified by PCR, using forward primer FAM-
AAGGGTACAGCGTCTCTCGG (Vb17) and the
same reverse primers as in real-time PCR. Each PCR
reaction contained 5 mL of cDNA, 1 U of Platinum-
Taq polymerase (Invitrogen), 2.5 mM MgCl2,
500 mM dNTPs, and 500 nM each primer. The reac-
tions were run at 95C for 9 minutes; then at 94Cfor 30 seconds, 58C for 30 seconds, and 72C for
30 seconds for 35 cycles; and finally at 72C for 30
minutes. The dye-labeled PCR products were de-
tected on an ABI 3100 sequence analyzer (PE Biosys-
tems); peaks were visualized, and their heights were
quantified using GeneScan software (Applied Biosys-
tems, Foster City, CA). If for cloning and sequencing,
only a single peak was excised from the gel and ana-
lyzed, then the peak size value was\100%. If all peaks
were excised and analyzed, then the value was 100%.
The decision whether to excise 1 peak or all peaks
was based on whether the peak heights showed
a Gaussian distribution (1 peak excised) or not (all
peaks excised), because only in the case of a Gaussian
distribution is it reasonable to assume that the peak
height is proportional to the diversity within the peak.
The number of different (distinct) sequences
within the peak(s) was determined by cloning and
sequencing, as follows. Vb17-Jb1.4, Vb17-Jb1.5, or
Vb17-Jb2.6 PCR products were separated by 2%
agarose gel and 12% polyacrylamide gel and then
extracted and purified using the QIAEX II Gel Extrac-
tion Kit (Qiagen, Foster City, CA) after cutting of sin-
gle or multiple band(s) under UV light. Purified PCR
products were inserted into vector pCR 2.1-TOPO
and transformed into DH5aT1-competent Escherichia
coli using the TOPO TA cloning Kit (Invitrogen). Af-
ter culture on LB plates with 100 mg/mL of ampicillin,
25 mg/mL of kanamycin, 0.1 mM IPTG, and 60 mg/
mL of X-gal for .12 hours, white or light blue colo-
nies were chosen as positive clones. Plasmid DNA
was sequenced using Bigdye dNTP (Applied Biosys-
tems), an ABI 373 sequencer, and ABI-PRISM soft-
ware. Clones were sequenced in batches of 20 until it
was obvious that no new distinct sequences would be
found (100 to 500 clones per each subject; time point
and Vb17-Jb combination) (Figure 1).RESULTS
The healthy control had 400,000 to 600,000 dis-
tinct Vb chains (Table 1), suggesting that the mini-
mum number of CD4 T cell clones in a normal
person is approximately 500,000. This result is close
to that obtained by Arstila et al. (800,000 to
1,200,000) [30]. Our estimate may be lower than that
of Arstila et al., because those authors used total T
cells, whereas we used CD4 T cells.
At 1 month posttransplantation, despite severe
CD4 T lymphopenia and very abnormal CD4 T cell
spectratypes, the calculated number of distinct Vb
chains was only 2- to 3-times lower than that detected
pretransplantation or found in the healthy control in
the SSc patient, and was similar to that in the healthy
control in the MS patient (Table 1). This unexpected
finding suggests that multiple T cell clones survived
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Figure 1. Example of sequencing clones in batches of 20 until it became
obvious that no new distinct sequences would be found.
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ing this treatment protocol, 2,000,000 CD4 T cells
typically are reinfused with the graft [29]). Consistent
with the finding that in the SSc patient, 2 of 2 domi-
nant (each sequenced . 50 times) Vb17 to -Jb1.4 se-
quences in the pretransplantation sample also were
detected in the 1-month posttransplantation sample.
In addition, 10 nondominant (each sequenced \ 10
times) Vb17 to -Jb1.4 sequences that were detected
in the pretransplantation sample were not detected in
the 1-month posttransplantation sample. It is unclear
whether these clones were located in extravascular
compartments at 1 month posttransplantation, were
undetectable in blood from technical reasons, or
were truly absent in this patient. The near-normal
number of distinct Vb chains at 1 month posttrans-
plantation likely was not due to the generation of
CD4 T cells de novo (ie, from hematopoietic stem
cells) in the first month posttransplantation, because
T cell receptor excision circles (TRECs) in adult autol-
ogous transplant recipients typically become detect-
able only at $ 3 months posttransplantation [24,29].
Consistent with this, in the 2 patients studied here,
TRECs were undetectable in CD4 T cells at 1 month
posttransplantation. The method of detection has
been discussed previously [29].
By 12 months posttransplantation, the diversity of
b chains in both patients became normal or near nor-
mal (Table 1). This can be attributed, at least in part,
to T cell generation de novo [24,25,29]. Consistent
with this finding, in the SSc patient, of the 16 distinct
Vb17 to -Jb1.4 sequences at 1 year posttransplanta-
tion, 15 were new sequences compared with those at
1 month posttransplantation. In the MS patient, of
the 230 distinct Vb17 to -Jb1.4 sequences at 1 year
posttransplantation, 196 were new compared with
those at 1 month posttransplantation. Also consistent
with de novo generation is the fact that both patientsexhibited a marked increase in phenotypically naı¨ve
(CD45RAhigh) CD4 T cell counts from 1 month to 1
year posttransplantation, from 1 to 72/mL in the SSc
patient and from 1 to 109/mL in the MS patient. The
method of detection has been described previously
[29]. Naı¨ve T cells are more diverse than memory/ef-
fector T cells [30].
Although CD8T cell diversity was not the focus of
this study, nevertheless, we wished to determine
whether, analogous to CD4T cells, pretransplantation
CD8 clones can persist after the lymphoablative condi-
tioning with autologous CD34 cell transplantation.
We explored this using cytomegalovirus (CMV)- and
Epstein-Barr virus (EBV)-specific CD8 clones. As
shown in Figure 2, in the MS patient, the same EBV-
specific CD8 clone that was present pretransplantation
also was present at 1 and 12 months posttransplanta-
tion. Similarly, in the SSc patient, the same EBV-spe-
cific and CMV-specific CD8 clones that were present
pretransplantation also were present posttransplanta-
tion. TRECs were undetectable in CD8 T cells at 1
month posttransplantation; thus, all 3 CD8 clones
studied likely survived the lymphoablative therapy.DISCUSSION
The unexpectedly large number of CD4 T cell
clones early after transplantation and the persistence
of herpesvirus-specific CD8 T cell clones from pre-
transplantation to posttransplantation may explain
why infections are relatively rare in autologous trans-
plant recipients after neutrophil engraftment [29]. It
also raises the question of whether clinical stabilization
or improvement of patients with autoimmune disease
after autologous transplantation is due to the condi-
tioning-induced elimination of most T cell clones (in-
cluding those causing the disease). On the one hand,
conditioning intensity appears to be inversely related
to the likelihood of autoimmune disease progression
[36], suggesting that debulking of pathogenic T cell
clones may be beneficial. On the other hand, Moore
et al. [37] found that clinical improvement of patients
with rheumatoid arthritis posttransplantation was not
inversely related to the number of T cells infused
with the autologous graft. Alternative explanations
for clinical stabilization or improvement of autoim-
mune disease after autograftingmay include functional
alteration of pathogenic T cell clones by the condi-
tioning, faster reconstitution of regulatory T cells
compared with effector T cells [38,39] and B lymphoa-
blation [40] (B cells are undetectable on day 7 with this
kind of transplant [29].)
When interpreting the results presented in Table
1, technical limitations should be kept in mind. First,
the number of distinct Vb chains is lower than the
number of T cell clones, because each b chain can
Figure 2. Persistence of CMV- and EBV-specific CD8 T cell clones, using allophycocyanin (APC)-labeled HLA-viral peptide tetramer analysis. Both pa-
tients were positive for HLA-A*0201; thus, we used NLVPMVATV (CMV peptide) conjugated to HLA-A*0201-APC tetramer and GLCTLVAML (EBV
peptide) conjugated to HLA*0201-APC tetramer (both purchased from Beckman Coulter) to stain CMV- and EBV-specific clones in blood mononuclear
cell specimens by flow cytometry. The cells also were stained by CD3-phycoerythrin antibody and CD8-fluorescein isothiocyanate (FITC) antibody. The
density dot plots, showing tetramer-APC fluorescence on the x-axis and CD8-FITC fluorescence on the y-axis, were gated on CD31CD81 lymphocytes.
The CMV tetramer staining of the cells from the MS patient (who was CMV-seronegative) served as a negative control for setting the border between
tetramer-positive and tetramer-negative cells. The percentages of the tetramer-positive cells (of total CD8 T cells) are shown, indicating that even
though the percentages varied, the same EBV-specific CD8 clones in both patients and the same CMV-specific CD8 clone in the CMV-seropositive pa-
tient were present both pretransplantation and posttransplantation.
Biol Blood Marrow Transplant 14:1373-1379, 2008 1377Posttransplantation T Cell Diversitycombine with various b chains. Thus, even though the
number of Vb chains may be near normal at 1 month
posttransplantation, the number of T cell clones at
this time theoretically may be significantly lower
than that in the same patient before transplantation
or in a healthy control. Nevertheless, the lack of
a marked difference in the number of distinct Vb
chains between 1 month posttransplantation and pre-
transplantation/healthy status suggests that the differ-
ence in the number of T cell clones is not extreme.
Second, the mathematical calculation of the diversity
of Vb specificities presented here assumes that the di-
versity within the Vb17-Jb1.4 segment is similar to the
diversity within other Vb-Jb segments. Theoretically,
this may not be true; however, the fact that the calcu-
lated diversity using Vb17-Jb1.5 or Vb17-Jb2.6 was
similar to that using Vb17-Jb1.4 (Table 1) suggestsa similar diversity within various Vb-Jb segments in
1 individual at 1 time point . Third, given the skewed
repertoire of posttransplantation T cells, underrepre-
sented sequences can be easily missed during the se-
quencing of cloned CDR3 segments unless many
clones are sequenced. We attempted to overcome
this problem by sequencing clones until it became ob-
vious that we would find no new distinct sequences (ie,
100 to 500 clones per each subject, time point and
Vb17-Jb combination). Packer and Muraro [41] re-
cently determined in autologous transplant recipients
that if only 75 to 100 clones were sequenced, then
the true number of distinct sequences would be under-
estimated, with an error of 5% to 7%. Thus, because
we analyzed 100 to 500 sequences, it is likely that we
underestimated the true number of distinct sequences
with an error of\ 7%.
1378 Biol Blood Marrow Transplant 14:1373-1379, 2008J. Storek et al.In conclusion, our findings suggest that the diver-
sity of CD4 T cells may be near normal 1 month after
Cy1TBI1ATG conditioning and autologous CD34
cell transplantation for autoimmune diseases. This
treatment may be only partially T cell–depleting
rather than completely T cell–ablative. Because the
treatment is not selective for certain T cell clones, at
least 1 cell or a few cells appear to be spared from
most T cell clones.ACKNOWLEDGMENTS
Financial disclosure: This work was supported by
National Institutes of Health Grant AI46108. J. S. is
a recipient of Canada Research Chair and Alberta
Heritage Foundation Clinical Scholar Awards. The
authors thank the staff of the Seattle Cancer Care Al-
liance Apheresis Unit and the patients for their willing-
ness to undergo research aphereses. They also thank
Dr Paolo A. Muraro for valuable input and the Seattle
Cancer Care Alliance Clinical HLA Laboratory for
HLA typing.REFERENCES
1. Villers D, Milpied N, Gaschet J, et al. Alteration of the T cell
repertoire after bone marrow transplantation. Bone Marrow
Transplant. 1994;13:19-26.
2. Gorski J, Yassai M, Keever C, et al. Analysis of reconstitution T
cell receptor repertoires in bone marrow transplant recipients.
Arch Immunol Ther Exp (Warsz). 1995;43:93-97.
3. Gorochov G, Debre P, Leblond V, et al. Oligoclonal expansion
of CD81CD571 T cells with restricted T cell receptor beta
chain variability after bone marrow transplantation. Blood.
1994;83:587-595.
4. Gaschet J, Denis C, Milpied N, et al. Alterations of T cell reper-
toire after bone marrow transplantation: characterization of over-
represented subsets. Bone Marrow Transplant. 1995;16:427-435.
5. Masuko K, Kato S, HagiharaM, et al. Stable clonal expansion of
T cells induced by bone marrow transplantation. Blood. 1996;87:
789-799.
6. Smith FS, Rencher SD, Heslop HE, et al. T cell receptor reper-
toire of CD41 and CD81 T cell subsets in the allogeneic bone
marrow transplant recipients. Cancer Immunol Immunother.
1995;41:104-110.
7. Roux E, Helg C, Chapuis B, et al. T cell repertoire complexity
after allogeneic bone marrow transplantation. Hum Immunol.
1996;48:135-138.
8. Roux E, Helg C, Dumont-Girard F, et al. Analysis of T cell re-
population after bonemarrow transplantation: significant differ-
ences between recipients of T cell depleted and unmanipulated
grafts. Blood. 1996;87:3984-3992.
9. Kubo K, Yamanaka K, Kiyoi H, et al. Different T cell receptor
repertoires between lesions and peripheral blood in acute
GVHD after allogeneic bone marrow transplantation. Blood.
1996;87:3019-3026.
10. Liu X, Chesnokova V, Forman SJ, et al. Molecular analysis of
T cell receptor repertoire in bone marrow transplant recipients:
evidence of oligoclonal T cell expansion in GVHD lesions.
Blood. 1996;87:3032-3044.
11. Vavassori M, Maccario R, Moretta A, et al. Restricted TCR
repertoire and long-term persistence of donor-derived antigen-
experienced CD4 T cells in allogeneic bone marrow transplan-
tation recipients. J Immunol. 1996;157:5739-5747.12. Akatsuka Y, Cerveny C, Hansen JA. T cell receptor clonal diver-
sity following allogeneic marrow grafting. Hum Immunol. 1996;
48:125-134.
13. Bomberger C, Singh-Jairam M, Rodey G, et al. Lymphoid
reconstitution after autologous PBSC transplantation with
FACS-sorted CD341 hematopoietic progenitors. Blood. 1998;
91:2588-2600.
14. Wu CJ, Chillemi A, Alyea EP, et al. Reconstitution of T-cell re-
ceptor repertoire diversity following T-cell–depleted allogeneic
bone marrow transplantation is related to hematopoietic chime-
rism. Blood. 2000;95:352-359.
15. Godthelp BC, van Tol MJ, Vossen JM, et al. T-cell immune re-
constitution in pediatric leukemia patients after allogeneic bone
marrow transplantation with T-cell–depleted or unmanipulated
grafts: evaluation of overall and antigen-specific T-cell reper-
toires. Blood. 1999;94:4358-4369.
16. Dumont-Girard F, Roux E, van Lier RA, et al. Reconstitution of
the T-cell compartment after bone marrow transplantation: res-
toration of the repertoire by thymic emigrants. Blood. 1998;92:
4464-4471.
17. Verfuerth S, Peggs K, Vyas P, et al. Longitudinal monitoring of
immune reconstitution by CDR3 size spectratyping after
T-cell–depleted allogeneic bone marrow transplant and the
effect of donor lymphocyte infusions on T-cell repertoire. Blood.
2000;95:3990-3995.
18. Bellucci R, Alyea EP,Weller E, et al. Immunologic effects of pro-
phylactic donor lymphocyte infusion after allogeneic marrow
transplantation for multiple myeloma. Blood. 2002;99:4610-4617.
19. Claret EJ, Alyea EP, Orsini E, et al. Characterization of T cell
repertoire in patients with graft-versus-leukemia after donor
lymphocyte infusion. J Clin Invest. 1997;100:855-866.
20. Eyrich M, Croner T, Leiler C, et al. Distinct contributions of
CD4(1) andCD8(1) naive andmemoryT-cell subsets to overall
T-cell receptor repertoire complexity following transplantation
of T-cell–depleted CD34-selected hematopoietic progenitor
cells from unrelated donors. Blood. 2002;100:1915-1918.
21. Friedman TM, Azhipa O, Zilberberg J, et al. Reconstitution of
T cell subset repertoire diversity following multiple antigen-
mismatched bone marrow transplantation. Biol Blood Marrow
Transplant. 2006;12:1092-1095.
22. RouxE,Dumont-Girard F, StarobinskiM, et al. Recovery of im-
mune reactivity after T-cell–depleted bone marrow transplanta-
tion depends on thymic activity. Blood. 2000;96:2299-2303.
23. Talvensaari K, Clave E, Douay C, et al. A broad T-cell reper-
toire diversity and an efficient thymic function indicate a favor-
able long-term immune reconstitution after cord blood stem cell
transplantation. Blood. 2002;99:1458-1464.
24. DouekDC,VescioRA,BettsMR, et al.Assessment of thymicout-
put in adults after haematopoietic stem cell transplantation and
prediction of T-cell reconstitution. Lancet. 2000;355:1875-1881.
25. Muraro PA, Douek DC, Packer A, et al. Thymic output gener-
ates a new and diverse TCR repertoire after autologous stem cell
transplantation in multiple sclerosis patients. J Exp Med. 2005;
201:805-816.
26. Protheroe AS, Pickard C, Johnson PW, et al. Persistence of
clonal T-cell expansions following high-dose chemotherapy
and autologous peripheral blood progenitor cell rescue. Br J
Haematol. 2000;111:766-773.
27. McSweeney PA,Nash RA, SullivanKM, et al. High-dose immu-
nosuppressive therapy for severe systemic sclerosis: initial out-
comes. Blood. 2002;100:1602-1610.
28. NashRA, Bowen JD,McSweeney PA, et al. High-dose immuno-
suppressive therapy and autologous peripheral blood stem cell
transplantation for severe multiple sclerosis. Blood. 2003;102:
2364-2372.
29. Storek J, Zhao Z, Lin E, et al. Recovery from and consequences
of severe iatrogenic lymphopenia (induced to treat autoimmune
diseases). Clin Immunol. 2004;113:285-298.
30. Arstila TP, Casrouge A, Baron V, et al. A direct estimate of the
human alphabeta T cell receptor diversity. Science. 1999;286:
958-961.
Biol Blood Marrow Transplant 14:1373-1379, 2008 1379Posttransplantation T Cell Diversity31. Del Galdo F, Artlett CM. T cells and B cells in the pathogenesis
of systemic sclerosis: recent insights and therapeutic opportuni-
ties. Curr Rheumatol Rep. 2006;8:123-130.
32. Frohman EM, RackeMK, Raine CS. Multiple sclerosis: the pla-
que and its pathogenesis. N Engl J Med. 2006;354:942-955.
33. KimDH, Sohn SK,WonDI, et al. Rapid helper T-cell recovery
above 200  106/L at 3 months correlates to successful trans-
plant outcomes after allogeneic stem cell transplantation. Bone
Marrow Transplant. 2006;37:1119-1128.
34. Storek J, GooleyT,Witherspoon RP, et al. Infectiousmorbidity
in long-term survivors of allogeneic marrow transplantation is
associated with low CD4 T cell counts. Am J Hematol. 1997;
54:131-138.
35. Lefranc M-P, Lefranc G. The T Cell Receptor FactsBook. San
Diego: Academic Press; 2001.
36. Gratwohl A, Passweg J, Bocelli-Tyndall C, et al. Autologous he-
matopoietic stem cell transplantation for autoimmune diseases.
Bone Marrow Transplant. 2005;35:869-879.37. Moore J, Brooks P, Milliken S, et al. A pilot randomized trial
comparing CD34-selected versus unmanipulated hemopoietic
stem cell transplantation for severe, refractory rheumatoid ar-
thritis. Arthritis Rheum. 2002;46:2301-2309.
38. ZhangH, Chua KS, GuimondM, et al. Lymphopenia and inter-
leukin-2 therapy alter homeostasis of CD41CD251 regulatory
T cells. Nat Med. 2005;11:1238-1243.
39. de Kleer I, Vastert B, Klein M, et al. Autologous stem cell trans-
plantation for autoimmunity induces immunologic self-toler-
ance by reprogramming autoreactive T cells and restoring the
CD41CD251 immune regulatory network. Blood. 2006;107:
1696-1702.
40. St Clair EW, Tedder TF. New prospects for autoimmune dis-
ease therapy: B cells on deathwatch. Arthritis Rheum. 2006;54:
1-9.
41. Packer AN,Muraro PA. Optimized clonotypic analysis of T-cell
receptor repertoire in immune reconstitution. Exp Hematol.
2007;35:516-521.
